+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Digital Biomarkers Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Product, Purpose of Solution, Type of Biomarker, Therapeutic Area, Business Model and Key Geographical Regions- Product Image
Digital Biomarkers Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Product, Purpose of Solution, Type of Biomarker, Therapeutic Area, Business Model and Key Geographical Regions- Product Image
New

Digital Biomarkers Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Product, Purpose of Solution, Type of Biomarker, Therapeutic Area, Business Model and Key Geographical Regions

  • PDF Icon

    Report

  • 369 Pages
  • April 2025
  • Region: Global
  • Roots Analysis
  • ID: 5306198
Description Jump to:

The global digital biomarkers market is estimated to grow from USD 5.6 billion in the current year to USD 35.8 billion by 2035, at a CAGR of 18.48% during the forecast period, to 2035.

Digital Biomarkers Market: Growth and Trends

Digital biomarker solutions are a combination of hardware and software features, such as sensors, and wearables, that monitor specific biomarkers in the human body that can be analyzed to generate significant insights about target indication(s). In modern healthcare, digital biomarkers help enhance diagnostic and therapeutic precision by enabling continuous monitoring and evaluation of clinically relevant health parameters. As per the report published by the United Nations, the population aged 65 years and above is projected to double reaching close to 1.5 billion in 2050. Owing to the rise in the prevalence of chronic disorders and the aging population, the overall healthcare costs are likely to be increased substantially over the coming years. Studies have shown that continuous symptom tracking with early intervention offers various benefits, such as improvement in the quality of life of patients and reduced medical management burden.

Further, the growing number of virtual and decentralized clinical studies has spurred the adoption of digital biomarkers that provide accurate, reliable and real-time health information without the need for frequent in-person visits by the patients. This trend promotes the participation of a large number of patients in clinical studies, offers a more patient-centric approach, and provides a more diverse and elaborate dataset of biomarkers. Driven by the rising adoption of remote patient monitoring solutions (specifically during chronic indications) and preference for personalized treatments, the digital biomarkers market is likely to grow at a significant pace in the foreseeable future.

Digital Biomarkers Market: Key Insights

The report delves into the current state of the digital biomarkers market and identifies potential growth opportunities within the industry.

Some key findings from the report include:

  • Presently, over 220 digital biomarker solutions are available / being developed by different players across the globe; of these, the majority of the solutions are data collection / analysis tools (specifically software platforms and wrist bands).

  • Over 40% of digital solutions collect / analyze data related to various physiological biomarkers (such as pulse rate, heart rate and body temperature); most of these are used for real-time monitoring of adults and older adults.
  • Several firms (encompassing startups as well as well-established companies), with varying resources, have been actively involved in this domain; the majority of these firms are based in North America.
  • Several industry as well as non-industry players have forged strategic deals in this domain; most of the intercontinental and intracontinental partnerships have been signed by players based in North America.
  • Foreseeing a lucrative potential within this domain, several firms have invested over USD 3 billion (across over 160 funding instances), since 2015; notably, majority of the funds were raised for developing imaging biomarkers.
  • In the past three years, over 50 events (offline and online) have been held to discuss the ongoing innovation and clinical outcomes in the digital biomarkers’ domain; further, around 55 eminent stakeholders have participated in these events.
  • Since 2019, over 750 patents related to digital biomarkers have been filed / granted to various stakeholders to protect the intellectual property generated within this domain.
  • The digital biomarkers market is anticipated to grow at an annualized rate (CAGR) of 18.5%, till 2035; the projected opportunity is likely to be distributed across different types of products, purposes of solutions and types of biomarkers.

The market opportunity for cell and gene therapy supply chain software has been distributed across the following segments:

Type of Product 

  • Software / Applications
  • Wearables
  • Sensors
  • Gaming Solutions 

Purpose of Solution 

  • Diagnosis
  • Early Detection
  • Monitoring
  • Predictive Insights

Type of Biomarker

  • Cognitive Biomarkers
  • Idiosyncratic Biomarkers
  • Physiological Biomarkers
  • Vocal Biomarkers
  • Other Biomarkers

Therapeutic Area 

  • Autoimmune Disorders
  • Cardiovascular Disorders
  • Infectious Diseases
  • Mental Health Disorders
  • Neurological Disorders
  • Respiratory Disorders
  • Substance Abuse Disorders
  • Others 

Business Model 

  • B2B
  • B2C

Key Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa
  • Rest of the World

Digital Biomarkers Market: Key Segments

Wearables Segment Occupies the Largest Share of the Digital Biomarkers Market

Based on the type of product, the market is segmented into software / applications, wearables, sensors and gaming solutions. At present, the wearables segment holds the maximum share of the digital biomarkers market. This can be attributed to the shifting preference of patients towards virtual consultations and telemedicine, and the growing prevalence of neurodegenerative disorders which in turn, has led to higher adoption of wearable digital biomarker solutions. It is worth highlighting that the digital biomarkers market for sensors is likely to grow at a relatively higher CAGR in the coming decade.

Monitoring Segment is Likely to Dominate the Digital Biomarkers Market During the Forecast Period

Based on the purpose of solution, the market is segmented into diagnosis, early detection, monitoring, and predictive insights. Currently, monitoring segment holds the maximum share of the digital biomarkers market. This can be attributed to the increasing prevalence of chronic disorders, which necessitates continuous tracking of health parameters of patients. It is worth noting that the digital biomarkers market for predictive insights is likely to grow at a relatively higher CAGR in the coming decade.

Physiological Biomarkers Occupy the Largest Share of the Digital Biomarkers Market

Based on the type of biomarker, the market is segmented into cognitive, idiosyncratic, physiological, vocal and other biomarkers. At present, the digital biomarker solutions that capture physiological biomarkers hold the maximum share of the digital biomarkers market. This can be attributed to high clinical validation of such biomarkers, compared to the other types of biomarkers, such as cognitive, idiosyncratic and vocal biomarkers. It is worth highlighting that the digital biomarkers market for vocal digital biomarkers is likely to grow at a relatively higher CAGR in the coming decade.

Neurological Disorders Account for the Largest Share of the Digital Biomarkers Market

Based on the therapeutic areas, the market is segmented into autoimmune disorders, cardiovascular disorders, infectious diseases, mental health disorders, neurological disorders, respiratory disorders, substance abuse disorders and other disorders. While neurological disorders account for a relatively higher market share, it is worth highlighting that the autoimmune disorders and substance abuse disorders segment is expected to witness substantial market growth in the coming years.

B2C Business Model Occupies the Largest Share of the Digital Biomarkers Market

Based on the business model, the market is segmented into B2B and B2C. At present, majority of the revenue is generated through the B2C business model. However, this trend is likely to evolve during the forecasted period, as developers are increasingly adopting B2B business models in order to maintain sustained growth.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the world. The majority share is expected to be captured by players based in North America. It is worth highlighting that, over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Sample Players in the Digital Biomarkers Market, Profiled in the Report Include:

  • Acculi Labs
  • ActiGraph
  • AliveCor
  • ATCOR
  • BACtrack
  • Biogen
  • BioSerenity
  • BioSensics
  • Eyenuk
  • Empatica
  • Feel Therapeutics
  • icometrix
  • iMediSync
  • IXICO
  • Kinsa
  • Koneksa Health
  • Kontigo Care
  • Progentec Diagnostics
  • Quibim
  • Vocalis Health

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

  • Founder and Chief Executive Officer, Small Company, India
  • Co-founder and Chief Executive Officer, Small Company, France
  • Business Development Manager, Mid-sized Company, UK 
  • Former Chief Commercial Officer, Small Company, Israel 

Digital Biomarkers Market: Research Coverage

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the digital biomarkers market, focusing on key market segments, including type of product, purpose of solution, type of biomarker, therapeutic area, business model and key geographical regions.
  • Market Landscape: A comprehensive evaluation of digital biomarker solutions, considering various parameters, such as type of product, type of digital biomarker solution, type of biomarker, status of development, purpose of biomarker, target therapeutic area, target population, type of end-user, clinical validation of biomarker solution and AI integration within biomarker solution. In addition, the chapter includes a detailed analysis of digital biomarkers developers, along with information on their year of establishment, company size (in terms of employee count), location of headquarters, type of business model and most active players (in terms of number of digital biomarker solutions offered).
  • Product Competitiveness Analysis: A comprehensive competitive analysis of digital biomarker solutions, examining factors, such as developer strength, product competitiveness and status of development.
  • Company Profiles: In-depth profiles of key digital biomarkers developers, focusing on company overviews, financial information (if available), digital biomarker portfolio, recent developments and an informed future outlook.
  • Partnerships and Collaborations: An analysis of partnerships established in this sector based on several parameters, such as year of partnership, type of partnership, type of biomarker, target therapeutic area, type of partner and  most active players (in terms of the number of partnerships signed). This section also highlights the regional distribution of partnership activity in this market.
  • Funding and Investment Analysis: A detailed evaluation of the investments made in this domain based on several parameters, such as year of funding, type of funding, amount invested (USD million), type of biomarker, therapeutic area, most active players (in terms of number of funding instances and amount raised), most active investors (in terms of number of funding instances) and regional distribution of funding.
  • Global Events Analysis: A detailed analysis of global events attended by the companies in the digital biomarkers industry, based on relevant parameters such as year of event, type of event, event platform, event organizer, location of event, and most active players, speakers and designations (in terms of number of events).
  • Patent Analysis: Detailed analysis of various patents filed / granted related to digital biomarkers based on type of patent (granted patents, patent applications and others), publication year, application year, patent jurisdiction, cooperative patent classification (CPC) symbols, type of applicant and most active players (in terms of the number of patents filed / granted). It also includes a patent benchmarking analysis and a detailed valuation analysis.
  • Big Pharma Analysis: A comprehensive examination of various initiatives focused on digital biomarkers undertaken by major pharmaceutical companies. This analysis various initiatives, such as number of clinical trials, number of collaborations, number of conferences attended, number of funding instances, and number of publications.
  • Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.

Key Questions Answered in this Report

  • How many companies are currently engaged in this market?
  • Which are the leading companies in this market?
  • What kind of partnership models are commonly adopted by industry stakeholders?
  • How much investment has been made by industry stakeholders in recent years?
  • What factors are likely to influence the evolution of this market?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

Additional Benefits

  • Complimentary PPT Insights Packs
  • Complimentary Excel Data Packs for all Analytical Modules in the Report
  • 10% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

Table of Contents

1. PREFACE
1.1. Digital Biomarker Solutions Market
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCHMETHODOLOGY
2.1 Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentation
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation
3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS
3.1 Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Future Estimates
3.2.2. Currency Coverage and Foreign Exchange Rate
3.2.2.1. Major Currencies Affecting the Market
3.2.2.2. Factors Affecting Currency Fluctuations and Foreign Exchange Rates
3.2.2.3. Impact of Foreign Exchange Rate Volatility on the Market
3.2.2.4. Strategies for Mitigating Foreign Exchange Risk
3.2.3. Trade Policies
3.2.3.1. Impact of Trade Barriers on the Market
3.2.3.2. Strategies for Mitigating the Risks Associated with Trade Barriers
3.2.4. Recession
3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY
5. INTRODUCTION
5.1 Chapter Overview
5.2. Overview of Digital Biomarkers
5.2.1. Classification of Digital Biomarkers
5.2.2. Types of Biological Signals Captured by Digital Biomarker Solutions
5.2.3. Key Advantages and Limitations
5.3. Product Development and Commercialization Path for Digital Biomarker Solutions
5.3.1. Discovery
5.3.2. Validations and Submissions
5.3.3. Distribution and Marketing
5.4. Recent Advancements related to Digital Biomarker Solutions
5.5. Impact of COVID-19 Pandemic on the Digital Biomarkers Domain
5.6. Prevalent Trends Related to Digital Biomarker Solutions
5.6.1. Emerging Focus Areas

6. MARKET LANDSCAPE
6.1. Chapter Overview
6.2. Digital Biomarker Solutions: Overall Market Landscape
6.2.1. Analysis by Type of Product
6.2.2. Analysis by Type of Digital Biomarker Solution
6.2.3. Analysis by Type of Biomarker
6.2.4. Analysis by Status of Development
6.2.5. Analysis by Type of Biomarker and Status of Development
6.2.6. Analysis by Purpose of Digital Biomarker Solution
6.2.7. Analysis by Target Therapeutic Area
6.2.8. Analysis by Type of Biomarker and Target Therapeutic Area
6.2.9. Analysis by Target Population
6.2.10. Analysis by End-user
6.2.11. Analysis by Availability of Clinical Validation
6.2.12. Analysis by Availability of Clinical Validates Solutions by Target Therapeutic Area
6.2.13. Analysis by Availability of AI Integration
6.3. Digital Biomarker Solutions: Developer Landscape
6.3.1. Analysis by Year of Establishment
6.3.2. Analysis by Company Size
6.3.3 Analysis by Location of Headquarters
6.3.4. Analysis by Company Size and Location of Headquarters
6.3.5. Most Active Players: Analysis by Number of Digital Biomarker Solutions Developed

7. PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Assumptions and Key Parameters
7.3. Methodology
7.4. Digital Biomarker Solutions: Product Competitiveness Analysis
7.4.1. Digital Biomarker Solutions Developed by Players based in North America
7.4.2. Digital Biomarker Solutions Developed by Players based in Europe
7.4.3. Digital Biomarker Solutions Developed by Players based in Asia-Pacific and Rest of the World

8. COMPANY PROFILES: DIGITAL BIOMARKER SOLUTIONS DEVELOPERS
8.1. Chapter Overview
8.2. Detailed Company Profiles of Leading Digital Biomarker Solutions Developers
8.2.1. BioSensics
8.2.1.1. Company Overview
8.2.1.2. Digital Biomarker Solutions Portfolio
8.2.1.3. Recent Developments and Future Outlook
8.2.2. AliveCor
8.2.2.1. Company Overview
8.2.2.2. Digital Biomarker Solutions Portfolio
8.2.2.3. Recent Developments and Future Outlook
8.2.3. BACtrack
8.2.3.1. Company Overview
8.2.3.2. Digital Biomarker Solutions Portfolio
8.2.3.3. Recent Developments and Future Outlook
8.2.4. Eyenuk
8.2.4.1. Company Overview
8.2.4.2. Digital Biomarker Solutions Portfolio
8.2.4.3. Recent Developments and Future Outlook
8.2.5. Quibim
8.2.5.1. Company Overview
8.2.5.2. Digital Biomarker Solutions Portfolio
8.2.5.3. Recent Developments and Future Outlook
8.2.6. Feel Therapeutics
8.2.6.1. Company Overview
8.2.6.2. Digital Biomarker Solutions Portfolio
8.2.6.3. Recent Developments and Future Outlook
8.2.7. Empatica
8.2.7.1. Company Overview
8.2.7.2. Digital Biomarker Solutions Portfolio
8.2.7.3. Recent Developments and Future Outlook
8.2.8. icometrix
8.2.8.1. Company Overview
8.2.8.2. Digital Biomarker Solutions Portfolio
8.2.8.3. Recent Developments and Future Outlook
8.2.9. Biogen
8.2.9.1. Company Overview
8.2.9.2. Digital Biomarker Solutions Portfolio
8.2.9.3. Recent Developments and Future Outlook
8.3. Short Company Profiles of Other Prominent Developers
8.3.1. Acculi Labs
8.3.1.1. Company Overview
8.3.1.2. Product Portfolio: Digital Biomarker Solutions
8.3.2. IXICO
8.3.2.1. Company Overview
8.3.2.2. Product Portfolio: Digital Biomarker Solutions
8.3.3. Kinsa
8.3.3.1. Company Overview
8.3.3.2. Product Portfolio: Digital Biomarker Solutions
8.3.4. Progentec Diagnostics
8.3.4.1. Company Overview
8.3.4.2. Product Portfolio: Digital Biomarker Solutions
8.3.5. Vocalis Health
8.3.5.1. Company Overview
8.3.5.2. Product Portfolio: Digital Biomarker Solutions
8.3.6. Kontigo Care
8.3.6.1. Company Overview
8.3.6.2. Product Portfolio: Digital Biomarker Solutions
8.3.7. Koneksa Health
8.3.7.1. Company Overview
8.3.7.2. Product Portfolio: Digital Biomarker Solutions
8.3.8. ActiGraph
8.3.8.1. Company Overview
8.3.8.2. Product Portfolio: Digital Biomarker Solutions
8.3.9. BioSerenity
8.3.9.1. Company Overview
8.3.9.2. Product Portfolio: Digital Biomarker Solutions
8.3.10. ATCOR
8.3.10.1. Company Overview
8.3.10.2. Product Portfolio: Digital Biomarker Solutions
8.3.11. iMediSync
8.3.11.1. Company Overview
8.3.11.2. Product Portfolio: Digital Biomarker Solutions

9. PARTNERSHIPS AND COLLABORATIONS
9.1. Chapter Overview
9.2. Partnership Models
9.3. Digital Biomarker Solutions: Partnerships and Collaborations
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Biomarker
9.3.5. Analysis by Type of Partnership and Type of Biomarker
9.3.6 Analysis by Therapeutic Area
9.3.7. Analysis of Type of Partnership and Therapeutic Area
9.3.8. Analysis by Type of Partner
9.3.9. Most Active Players: Analysis by Number of Partnerships
9.3.10. Analysis by Geography
9.3.10.1. Intracontinental and Intercontinental Deals
9.3.10.2. International and Local Deals
10. FUNDING AND INVESTMENTS
10.1. Chapter Overview
10.2. Funding Models
10.3. Digital Biomarker Solutions: Funding and Investments
10.3.1. Analysis by Year of Investment
10.3.2. Analysis by Amount Invested
10.3.3. Analysis of Funding Instances by Type of Funding
10.3.4. Analysis of Amount Invested by Type of Funding
10.3.5. Analysis of Funding Instances by Type of Biomarker
10.3.6. Analysis of Funding Instances and Amount Invested by Therapeutic Area
10.3.7. Leading Investors: Distribution by Number of Funding Instances
10.3.8. Most Active Players: Distribution by Number of Funding Instances
10.3.9. Most Active Players: Analysis by Amount Raised
10.3.10. Most Active Players: Analysis by Geography
11. GLOBAL EVENTS ANALYSIS
11.1. Chapter Overview
11.2. Scope and Methodology
11.3. Digital Biomarker Solutions: Global Events Analysis
11.3.1. Analysis by Year of Event
11.3.2. Analysis by Type of Event
11.3.3. Analysis by Year and Type of Event
11.3.4. Analysis by Event Platform
11.3.5. Analysis by Location of Event
11.3.6. Word Cloud Analysis: Key Focus Areas
11.3.7. Most Active Event Organizers: Analysis by Number of Events
11.3.8. Most Active Players: Analysis by Number of Events
11.4. Global Events: Speaker Analysis
11.4.1. Most Active Speakers: Analysis by Number of Events
11.4.2. Analysis by Designation / Qualification of Speakers
11.5. List of Upcoming Global Events
11.6. Concluding Remarks
12. PATENT ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Digital Biomarker Solutions: Patent Analysis
12.3.1. Analysis by Patent Application Year
12.3.2. Analysis by Patent Publication Year
12.3.3. Analysis by Type of Patent and Patent Publication Year
12.3.4. Analysis by Patent Jurisdiction
12.3.5. Analysis by CPC Symbols
12.3.6. Analysis by Patent Publication Year and Type of Applicant
12.3.7. Leading Players: Analysis by Number of Patents
12.3.8. Leading Patent Assignees: Analysis by Number of Patents
12.4. Patent Benchmarking Analysis
12.4.1. Analysis By Patent Characteristics
12.5. Patent Valuation
12.6. Leading Patents by Number of Citations

13. BIG PHARMA INITIATIVES
13.1. Chapter Overview
13.2. Methodology and Key Parameters
13.3. Big Pharma Initiatives Related to Digital Biomarker Solutions
13.3.1. Analysis by Type of Initiatives
13.3.2. Heat Map Analysis
13.4. Big Pharma Players: Benchmark Analysis
13.4.1. Spider Web Analysis: AbbVie
13.4.2. Spider Web Analysis: Amgen
13.4.3. Spider Web Analysis: AstraZeneca
13.4.4. Spider Web Analysis: Bayer
13.4.5. Spider Web Analysis: Bristol Myers Squibb
13.4.6. Spider Web Analysis: Eli Lilly
13.4.7. Spider Web Analysis: GlaxoSmithKline
13.4.8. Spider Web Analysis: Johnson & Johnson
13.4.9. Spider Web Analysis: Merck
13.4.10. Spider Web Analysis: Novartis
13.4.11. Spider Web Analysis: Pfizer
13.4.12. Spider Web Analysis: Roche
13.4.13. Spider Web Analysis: Sanofi
13.4.14. Spider Web Analysis: Takeda Pharmaceuticals
13.5. Most Active Players: Distribution by Number of Initiatives

14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES
14.1. Chapter Overview
14.2. Market Drivers
14.3. Market Restraints
14.4. Market Opportunities
14.5. Market Challenges
14.6. Conclusion

15. GLOBAL DIGITAL BIOMARKER SOLUTIONS MARKET
15.1. Chapter Overview
15.2. Assumptions and Methodology
15.3. Global Digital Biomarker Solutions Market, Historical Trends (2018-2023) and Future Estimates (2024-2035)
15.3.1. Scenario Analysis
15.3.1.1. Conversative Scenario
15.3.1.2. Optimistic Scenario
15.4. Key Market Segmentation

16. DIGITAL BIOMARKER SOLUTIONS MARKET, BY TYPE OF PRODUCT
16.1. Chapter Overview
16.2. Assumptions and Methodology
16.3. Digital Biomarker Solutions Market: Distribution by Type of Product, 2018, 2024 and 2035
16.3.1. Digital Biomarker Solutions Market for Software / Applications: Historical Trends (2018-2023) and Future Estimates (2024-2035)
16.3.2. Digital Biomarker Solutions Market for Wearables: Historical Trends Historical Trends (2018-2023) and Future Estimates (2024-2035)
16.3.3. Digital Biomarker Solutions Market for Sensors: Historical Trends (2018-2023) and Future Estimates (2024-2035)
16.3.4. Digital Biomarker Solutions Market for Gaming Solutions: Historical Trends (2018-2023) and Future Estimates (2024-2035)
16.4. Data Triangulation and Validation

17. DIGITAL BIOMARKER SOLUTIONS MARKET, BY PURPOSE OF SOLUTION
17.1. Chapter Overview
17.2. Assumptions and Methodology
17.3. Digital Biomarker Solutions Market: Distribution by Purpose of Solution, 2018, 2024 and 2035
17.3.1. Digital Biomarker Solutions Market for Monitoring: Historical Trends (2018-2023) and Future Estimates (2024-2035)
17.3.2. Digital Biomarker Solutions Market for Diagnosis: Historical Trends (2018-2023) and Future Estimates (2024-2035)
17.3.3. Digital Biomarker Solutions Market for Early Detection: Historical Trends (2018-2023) and Future Estimates (2024-2035)
17.3.4. Digital Biomarker Solutions Market for Predictive Insights: Historical Trends (2018-2023) and Future Estimates (2024-2035)
17.4. Data Triangulation and Validation
18. DIGITAL BIOMARKER SOLUTIONS MARKET, BY TYPE OF BIOMARKER
18.1. Chapter Overview
18.2. Assumptions and Methodology
18.3. Digital Biomarker Solutions Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
18.3.1. Digital Biomarker Solutions Market for Physiological Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.2. Digital Biomarker Solutions Market for Vocal Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.3. Digital Biomarker Solutions Market for Cognitive Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.4. Digital Biomarker Solutions Market for Idiosyncratic Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.3.5. Digital Biomarker Solutions Market for Other Biomarkers: Historical Trends (2018-2023) and Future Estimates (2024-2035)
18.4. Data Triangulation and Validation
19. DIGITAL BIOMARKER SOLUTIONS MARKET, BY THERAPEUTIC AREA
19.1. Chapter Overview
19.2. Assumptions and Methodology
19.3. Digital Biomarker Solutions Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
19.3.1. Digital Biomarker Solutions Market for Neurological Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.2. Digital Biomarker Solutions Market for Mental Health Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.3. Digital Biomarker Solutions Market for Cardiovascular Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.4. Digital Biomarker Solutions Market for Infectious Diseases: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.5. Digital Biomarker Solutions Market for Respiratory Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.6. Digital Biomarker Solutions Market for Autoimmune Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.7. Digital Biomarker Solutions Market for Substance Abuse Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.3.8. Digital Biomarker Solutions Market for Other Disorders: Historical Trends (2018-2023) and Future Estimates (2024-2035)
19.4. Data Triangulation and Validation
20. DIGITAL BIOMARKER SOLUTIONS MARKET, BY BUSINESS MODEL
20.1. Chapter Overview
20.2. Assumptions and Methodology
20.3. Digital Biomarker Solutions Market: Distribution by Business Model, 2018, 2024 and 2035
20.3.1. Digital Biomarker Solutions Market for B2B Model: Historical Trends (2018-2023) and Future Estimates (2024-2035)
20.3.2. Digital Biomarker Solutions Market for B2C Model: Historical Trends (2018-2023) and Future Estimates (2024-2035)
20.4. Data Triangulation and Validation
21. DIGITAL BIOMARKER SOLUTIONS MARKET, BY KEY GEOGRAPHICAL REGIONS
21.1. Chapter Overview
21.2. Assumptions and Methodology
21.3. Digital Biomarker Solutions Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
21.3.1. Digital Biomarker Solutions Market in North America: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.2. Digital Biomarker Solutions Market in Europe: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.3. Digital Biomarker Solutions Market in Asia-Pacific: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.4. Digital Biomarker Solutions Market in Middle East and North Africa (MENA): Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.3.5. Digital Biomarker Solutions Market in Rest of the World: Historical Trends (2018-2023) and Future Estimates (2024-2035)
21.4. Data Triangulation and Validation
22. CONCLUDING REMARKS
23. EXECUTIVE INSIGHTS
23.1. Chapter Overview
23.2. Acculi Labs
23.2.1. Company Snapshot
23.2.2. Interview Transcript: Rupam Das, Chief Executive Officer
23.3. IXICO
23.3.1. Company Snapshot
23.3.2. Interview Transcript: Rohan Sopp, Business Development Manager
23.4. Tilak Healthcare
23.4.1. Company Snapshot
23.4.2. Interview Transcript: Edouard Gasser, Co-Founder and Chief Executive Officer
23.5. Vocalis Health
23.5.1. Company Snapshot
23.5.2. Interview Transcript: Michael Seggev, Former Chief Commercial Officer

24. APPENDIX 1: TABULATED DATA25. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION
LIST OF FIGURES
Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Digital Biomarker Solutions Market Landscape
Figure 4.2 Executive Summary: Digital Biomarker Solution Developer Landscape
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Funding and Investments
Figure 4.5 Executive Summary: Global Events Analysis
Figure 4.6 Executive Summary: Patent Analysis
Figure 4.7 Executive Summary: Digital Biomarker Solutions Market Forecast and Opportunity Analysis
Figure 5.1 Types of Digital Biomarkers
Figure 5.2 Types of Biomarkers / Signals Captured by Digital Biomarker Solutions
Figure 5.3 Emerging Focus Areas: Google News
Figure 6.1 Digital Biomarker Solutions: Distribution by Type of Product
Figure 6.2 Digital Biomarker Solutions: Distribution by Type of Digital Biomarker Solution
Figure 6.3 Digital Biomarker Solutions: Distribution by Type of Biomarker
Figure 6.4 Digital Biomarker Solutions: Distribution by Status of Development
Figure 6.5 Digital Biomarker Solutions: Distribution by Type of Biomarker and Status of Development
Figure 6.6 Digital Biomarker Solutions: Distribution by Purpose of Digital Biomarker Solution
Figure 6.7 Digital Biomarker Solutions: Distribution by Target Therapeutic Area
Figure 6.8 Digital Biomarker Solutions: Distribution by Type of Biomarker and Target Therapeutic Area
Figure 6.9 Digital Biomarker Solutions: Distribution by Target Population
Figure 6.10 Digital Biomarker Solutions: Distribution by End-user
Figure 6.11 Digital Biomarker Solutions: Distribution by Availability of Clinical Validation
Figure 6.12 Digital Biomarker Solutions: Distribution of Clinically Validated Solutions by Target Therapeutic Area
Figure 6.13 Digital Biomarker Solutions: Distribution by Availability of AI Integration
Figure 6.14 Digital Biomarker Solution Developers: Distribution by Year of Establishment
Figure 6.15 Digital Biomarker Solution Developers: Distribution by Company Size
Figure 6.16 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Region)
Figure 6.17 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Country)
Figure 6.18 Digital Biomarker Solution Developers: Distribution by Company Size and Location of Headquarters
Figure 6.19 Most Active Players: Distribution by Number of Digital Biomarker Solutions Developed
Figure 7.1 Product Competitiveness Analysis: Digital Biomarker Solutions Developed by Players based in North America
Figure 7.2 Product Competitiveness Analysis: Digital Biomarker Solutions Developed by Players based in Europe
Figure 7.3 Product Competitiveness Analysis: Digital Biomarker Solutions Developed by Players based in Asia-Pacific and Rest of the World
Figure 9.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2019 - 2024
Figure 9.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 9.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships and Collaborations: Distribution by Type of Biomarker
Figure 9.5 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biomarker
Figure 9.6 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 9.7 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Figure 9.8 Partnerships and Collaborations: Distribution by Type of Partner
Figure 9.9 Most Active Players: Distribution by Number of Partnerships
Figure 9.10 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Figure 9.11 Partnerships and Collaborations: International and Local Deals
Figure 10.1 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, Pre-2018-2024
Figure 10.2 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, Pre-2018-2024
Figure 10.3 Funding and Investment: Distribution by Type of Funding
Figure 10.4 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 10.5 Funding and Investments: Distribution by Type of Biomarker
Figure 10.6 Funding and Investments: Distribution by Therapeutic Area
Figure 10.7 Leading Investors: Distribution by Number of Funding Instances
Figure 10.8 Most Active Players: Distribution by Number of Funding Instances
Figure 10.9 Most Active Players: Distribution by Amount Raised
Figure 10.10 Funding and Investments: Distribution by Geography (Region)
Figure 10.11 Funding and Investments: Distribution by Geography (Country)
Figure 11.1 Global Events Analysis: Cumulative Year-wise Trend, H1 2021 - H1 2024
Figure 11.2 Global Events Analysis: Distribution by Type of Event
Figure 11.3 Global Events Analysis: Distribution by Year and Type of Event
Figure 11.4 Global Events Analysis: Distribution by Event Platform
Figure 11.5 Global Events Analysis: Distribution by Location of Event (Region)
Figure 11.6 Global Events Analysis: Distribution by Location of Event (Country)
Figure 11.7 Word Cloud Analysis: Key Focus Areas
Figure 11.8 Most Active Event Organizers: Distribution by Number of Events
Figure 11.9 Most Active Players: Distribution by Number of Events
Figure 11.10 Most Active Speakers: Distribution by Number of Events
Figure 11.11 Distribution by Designation / Qualification of Speakers
Figure 12.1 Patent Analysis: Distribution by Type of Patent
Figure 12.2 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2018-2023
Figure 12.3 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, 2019-2023
Figure 12.4 Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2019-2023
Figure 12.5 Patent Analysis: Distribution by Patent Jurisdiction (Region)
Figure 12.6 Patent Analysis: Distribution by Patent Jurisdiction (Country)
Figure 12.7 Patent Analysis: Distribution by CPC Symbols
Figure 12.8 Patent Analysis: Distribution by Patent Publication Year and Type of Applicant
Figure 12.9 Leading Players: Distribution by Number of Patents
Figure 12.10 Leading Patent Assignees: Distribution by Number of Patents
Figure 12.11 Patent Benchmarking: Distribution of Patent Characteristics (CPC Codes) by Leading Players
Figure 12.12 Patent Benchmarking: Distribution of Leading Players by Patent Characteristics (Top CPC Codes)
Figure 12.13 Patent Analysis: Distribution by Patent Age
Figure 12.14 Digital Biomarker Solutions: Patent Valuation
Figure 13.1 Big Pharma Initiatives Related to Digital Biomarker Solutions: Distribution by Type of Initiative
Figure 13.2 Big Pharma Initiatives Related to Digital Biomarker Solutions: Heat Map Analysis
Figure 13.3 Spider Web Analysis: AbbVie
Figure 13.4 Spider Web Analysis: Amgen
Figure 13.5 Spider Web Analysis: AstraZeneca
Figure 13.6 Spider Web Analysis: Bayer
Figure 13.7 Spider Web Analysis: Bristol Myers Squibb
Figure 13.8 Spider Web Analysis: Eli Lilly
Figure 13.9 Spider Web Analysis: GlaxoSmithKline
Figure 13.10 Spider Web Analysis: Johnson & Johnson
Figure 13.11 Spider Web Analysis: Merck
Figure 13.12 Spider Web Analysis: Novartis
Figure 13.13 Spider Web Analysis: Pfizer
Figure 13.14 Spider Web Analysis: Roche
Figure 13.15 Spider Web Analysis: Sanofi
Figure 13.16 . Spider Web Analysis: Takeda Pharmaceuticals
Figure 13.17 Most Active Players: Distribution by Number of Initiatives
Figure 15.1 Global Digital Biomarker Solutions Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 15.2 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Million)
Figure 15.3 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Million)
Figure 16.1 Digital Biomarker Solutions Market: Distribution by Type of Product, 2018, 2024 and 2035
Figure 16.2 Digital Biomarker Solutions Market for Software / Applications: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 16.3 Digital Biomarker Solutions Market for Wearables: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 16.4 Digital Biomarker Solutions Market for Sensors: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 16.5 Digital Biomarker Solutions Market for Gaming Solutions: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 17.1 Digital Biomarker Solutions Market: Distribution by Purpose of Solution, 2018, 2024 and 2035
Figure 17.2 Digital Biomarker Solutions Market for Monitoring: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 17.3 Digital Biomarker Solutions Market for Diagnosis: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 17.4 Digital Biomarker Solutions Market for Early Detection: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 17.5 Digital Biomarker Solutions Market for Predictive Insights: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 18.1 Digital Biomarker Solutions Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
Figure 18.2 Digital Biomarker Solutions Market for Physiological Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 18.3 Digital Biomarker Solutions Market for Vocal Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 18.4 Digital Biomarker Solutions Market for Cognitive Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 18.5 Digital Biomarker Solutions Market for Idiosyncratic Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 18.6 Digital Biomarker Solutions Market for Other Biomarkers: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 19.1 Digital Biomarker Solutions Market: Distribution by Therapeutic Area, 2018, 2024 and 2035
Figure 19.2 Digital Biomarker Solutions Market for Neurological Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 19.3 Digital Biomarker Solutions Market for Mental Health Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 19.4 Digital Biomarker Solutions Market for Cardiovascular Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 19.5 Digital Biomarker Solutions Market for Infectious Diseases: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 19.6 Digital Biomarker Solutions Market for Respiratory Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 19.7 Digital Biomarker Solutions Market for Autoimmune Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 19.8 Digital Biomarker Solutions Market for Substance Abuse Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 19.9 Digital Biomarker Solutions Market for Other Disorders: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.1 Digital Biomarker Solutions Market: Distribution by Business Model, 2018, 2024 and 2035
Figure 20.2 Digital Biomarker Solutions Market for B2B Model: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 20.3 Digital Biomarker Solutions Market for B2C Model: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.1 Digital Biomarker Solutions Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Figure 21.2 Digital Biomarker Solutions Market in North America: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.3 Digital Biomarker Solutions Market in Europe: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.4 Digital Biomarker Solutions Market in Asia-Pacific: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.5 Digital Biomarker Solutions Market in Middle East and North Africa: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 21.6 Digital Biomarker Solutions Market in Rest of the World: Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 22.1 Concluding Remarks: Digital Biomarker Solutions Market Landscape
Figure 22.2 Concluding Remarks: Digital Biomarker Solution Developers Landscape
Figure 22.3 Concluding Remarks: Partnerships and Collaborations
Figure 22.4 Concluding Remarks: Funding and Investment
Figure 22.5 Concluding Remarks: Global Events Analysis
Figure 22.6 Concluding Remarks: Patent Analysis
Figure 22.7 Concluding Remarks: Market Sizing and Opportunity Analysis (I/II)
Figure 22.8 Concluding Remarks: Market Sizing and Opportunity Analysis (II/II)

LIST OF TABLES
Table 5.1 Key Advantages and Limitations for Digital Biomarkers
Table 6.1 Digital Biomarker Solutions: Overall Market Landscape
Table 6.2 Digital Biomarker Solutions: Information on Status of Development, Approving Authority, Launch Data and Purpose of Biomarker Solutions
Table 6.3 Digital Biomarker Solutions: Information on Target Indication, Target Therapeutic Area, Target Population and Target Segment
Table 6.4 Digital Biomarker Solutions: Information on Solution Specifications, End-user, Clinical Validation and AI Integration
Table 6.5 Digital Biomarker Solutions: Developers Landscape
Table 8.1 Players Developing Digital Biomarker Solutions: List of Companies Profiled
Table 8.2 BioSensics: Company Snapshot
Table 8.3 BioSensics: Digital Biomarker Solutions Portfolio
Table 8.4 BioSensics: Recent Developments and Future Outlook
Table 8.5 Eyenuk: Company Snapshot
Table 8.6 Eyenuk: Digital Biomarker Solutions Portfolio
Table 8.7 Eyenuk: Recent Developments and Future Outlook
Table 8.8 Quibim: Company Snapshot
Table 8.9 Quibim: Digital Biomarker Solutions Portfolio
Table 8.10 Quibim: Recent Developments and Future Outlook
Table 8.11 Feel Therapeutics: Company Snapshot
Table 8.12 Feel Therapeutics: Digital Biomarker Solutions Portfolio
Table 8.13 Feel Therapeutics: Recent Developments and Future Outlook
Table 8.14 AliveCor: Company Snapshot
Table 8.15 AliveCor: Digital Biomarker Solutions Portfolio
Table 8.16 AliveCor: Recent Developments and Future Outlook
Table 8.17 BACtrack: Company Snapshot
Table 8.18 BACtrack: Digital Biomarker Solutions Portfolio
Table 8.19 Empatica: Company Snapshot
Table 8.20 Empatica: Digital Biomarker Solutions Portfolio
Table 8.21 Empatica: Recent Developments and Future Outlook
Table 8.22 icometrix: Company Snapshot
Table 8.23 icometrix: Digital Biomarker Solutions Portfolio
Table 8.24 icometrix: Recent Developments and Future Outlook
Table 8.25 Biogen: Company Snapshot
Table 8.26 Biogen: Digital Biomarker Solutions Portfolio
Table 8.27 Biogen: Recent Developments and Future Outlook
Table 8.28 Acculi Labs: Company Snapshot
Table 8.29 Acculi Labs: Digital Biomarker Solutions Portfolio
Table 8.30 IXICO: Company Snapshot
Table 8.31 IXICO: Digital Biomarker Solutions Portfolio
Table 8.32 Kinsa: Company Snapshot
Table 8.33 Kinsa: Digital Biomarker Solutions Portfolio
Table 8.34 Progentec Diagnostics: Company Snapshot
Table 8.35 Progentec Diagnostics: Digital Biomarker Solutions Portfolio
Table 8.36 Vocalis Health: Company Snapshot
Table 8.37 Vocalis Health: Digital Biomarker Solutions Portfolio
Table 8.38 Kontigo Care: Company Snapshot
Table 8.39 Kontigo Care: Digital Biomarker Solutions Portfolio
Table 8.40 Koneksa Health: Company Snapshot
Table 8.41 Koneksa Health: Digital Biomarker Solutions Portfolio
Table 8.42 ActiGraph: Company Snapshot
Table 8.43 ActiGraph: Digital Biomarker Solutions Portfolio
Table 8.44 BioSerenity: Company Snapshot
Table 8.45 BioSerenity: Digital Biomarker Solutions Portfolio
Table 8.46 ATCOR: Company Snapshot
Table 8.47 ATCOR: Digital Biomarker Solutions Portfolio
Table 8.48 iMediSync: Company Snapshot
Table 8.49 iMediSync: Digital Biomarker Solutions Portfolio
Table 9.1 Digital Biomarker Solutions: List of Partnerships and Collaborations, Pre-2019-2024
Table 10.1 Digital Biomarker Solutions: List of Funding and Investments, Pre-2018-2024
Table 11.1 Digital Biomarker Solutions: List of Global Events
Table 11.2 Global Events Analysis: Information on Name of Speakers and their Designations
Table 12.1 Patent Analysis: Top CPC Sections
Table 12.2 Patent Analysis: Top CPC Symbols
Table 12.3 Patent Analysis: List of Top CPC Codes
Table 12.4 Patent Analysis: Summary of Benchmarking Analysis
Table 12.5 Patent Analysis: Categorization based on Weighted Valuation Scores
Table 12.6 Patent Portfolio: List of Leading Patents (by Highest Relative Valuation)
Table 23.1 Acculi Labs: Company Snapshot
Table 23.2 IXICO: Company Snapshot
Table 23.3 Tilak Healthcare: Company Snapshot
Table 23.4 Vocalis Health: Company Snapshot
Table 24.1 Digital Biomarker Solutions: Distribution by Type of Product
Table 24.2 Digital Biomarker Solutions: Distribution by Type of Digital Biomarker Solution
Table 24.3 Digital Biomarker Solutions: Distribution by Type of Biomarker
Table 24.4 Digital Biomarker Solutions: Distribution by Status of Development
Table 24.5 Digital Biomarker Solutions: Distribution by Type of Biomarker and Status of Development
Table 24.6 Digital Biomarker Solutions: Distribution by Purpose of Digital Biomarker Solution
Table 24.7 Digital Biomarker Solutions: Distribution by Target Therapeutic Area
Table 24.8 Digital Biomarker Solutions: Distribution by Type of Biomarker and Target Therapeutic Area
Table 24.9 Digital Biomarker Solutions: Distribution by Target Population
Table 24.10 Digital Biomarker Solutions: Distribution by End-user
Table 24.11 Digital Biomarker Solutions: Distribution by Availability of Clinical Validation
Table 24.12 Digital Biomarker Solutions: Distribution of Clinically Validated Solutions by Target Therapeutic Area
Table 24.13 Digital Biomarker Solutions: Distribution by Availability of AI Integration
Table 24.14 Digital Biomarker Solution Developers: Distribution by Year of Establishment
Table 24.15 Digital Biomarker Solution Developers: Distribution by Company Size
Table 24.16 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Region)
Table 24.17 Digital Biomarker Solution Developers: Distribution by Location of Headquarters (Country)
Table 24.18 Digital Biomarker Solution Developers: Distribution by Company Size and Location of Headquarters
Table 24.19 Most Active Players: Distribution by Number of Digital Biomarker Solutions Developed
Table 24.20 Partnerships and Collaborations: Cumulative Year-Wise Trend, Pre-2019 - 2024
Table 24.21 Partnerships and Collaborations: Distribution by Type of Partnership
Table 24.22 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 24.23 Partnerships and Collaborations: Distribution by Type of Biomarker
Table 24.24 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biomarker
Table 24.25 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 24.26 Partnerships and Collaborations: Distribution by Type of Partnership and Therapeutic Area
Table 24.27 Partnerships and Collaborations: Distribution by Type of Partner
Table 24.28 Most Active Players: Distribution by Number of Partnerships
Table 24.29 Partnerships and Collaborations: Intercontinental and Intracontinental Deals
Table 24.30 Partnerships and Collaborations: International and Local Deals
Table 24.31 Funding and Investments: Cumulative Year-wise Trend of Funding Instances, Pre-2018-2024
Table 24.32 Funding and Investments: Cumulative Year-wise Trend of Amount Invested, Pre-2018-2024
Table 24.33 Funding and Investment: Distribution by Type of Funding
Table 24.34 Funding and Investments: Distribution of Amount Invested by Type of Funding (USD Million)
Table 24.35 Funding and Investments: Distribution by Type of Biomarker
Table 24.36 Funding and Investments: Distribution by Therapeutic Area
Table 24.37 Leading Investors: Distribution by Number of Funding Instances
Table 24.38 Most Active Players: Distribution by Number of Funding Instances
Table 24.39 Most Active Players: Distribution by Amount Raised
Table 24.40 Funding and Investments: Distribution by Geography (Region)
Table 24.41 Funding and Investments: Distribution by Geography (Country)
Table 24.42 Global Events Analysis: Cumulative Year-wise Trend, H1 2021 - H1 2024
Table 24.43 Global Events Analysis: Distribution by Type of Event
Table 24.44 Global Events Analysis: Distribution by Year and Type of Event
Table 24.45 Global Events Analysis: Distribution by Event Platform
Table 24.46 Global Events Analysis: Distribution by Location of Event (Region)
Table 24.47 Global Events Analysis: Distribution by Location of Event (Country)
Table 24.48 Most Active Event Organizers: Distribution by Number of Events
Table 24.49 Most Active Players: Distribution by Number of Events
Table 24.50 Most Active Speakers: Distribution by Number of Events
Table 24.51 Distribution by Designation / Qualification of Speakers
Table 24.52 Patent Analysis: Distribution by Type of Patent
Table 24.53 Patent Analysis: Cumulative Year-wise Trend by Patent Application Year, Pre-2018-2023
Table 24.54 Patent Analysis: Cumulative Year-wise Trend by Patent Publication Year, 2019-2023
Table 24.55 Patent Analysis: Distribution by Type of Patent and Patent Publication Year, 2019-2023
Table 24.56 Patent Analysis: Distribution by Patent Jurisdiction (Region)
Table 24.57 Patent Analysis: Distribution by Patent Jurisdiction (Country)
Table 24.58 Patent Analysis: Distribution by Patent Publication Year and Type of Applicant
Table 24.59 Leading Players: Distribution by Number of Patents
Table 24.60 Leading Patent Assignees: Distribution by Number of Patents
Table 24.61 Patent Analysis: Distribution by Patent Age
Table 24.62 Digital Biomarker Solutions: Patent Valuation
Table 24.63 Global Digital Biomarker Solutions Market, Historical Trends (2018-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 24.64 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Million)
Table 24.65 Global Digital Biomarker Solutions Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Million)
Table 24.66 Digital Biomarker Solutions Market for Software / Applications, Historical Trends (2018-2023) (USD Million)
Table 24.67 Digital Biomarker Solutions Market: Distribution by Type of Product, 2018, 2024 and 2035
Table 24.68 Digital Biomarker Solutions Market for Wearables, Historical Trends (2018-2023) (USD Million)
Table 24.69 Digital Biomarker Solutions Market for Software / Applications, Forecasted Estimates (2024-2035) (USD Million)
Table 24.70 Digital Biomarker Solutions Market for Sensors, Historical Trends (2018-2023) (USD Million)
Table 24.71 Digital Biomarker Solutions Market for Wearables, Forecasted Estimates (2024-2035) (USD Million)
Table 24.72 Digital Biomarker Solutions Market for Gaming Solutions, Historical Trends (2018-2023) (USD Million)
Table 24.73 Digital Biomarker Solutions Market for Gaming Solutions, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.74 Biomarker Solutions Market: Distribution by Purpose of Solution, 2018, 2024 and 2035
Table 24.75 Biomarker Solutions Market for Monitoring, Historical Trends (2018-2023) (USD Million)
Table 24.76 Digital Biomarker Solutions Market for Monitoring, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.77 Biomarker Solutions Market for Diagnosis, Historical Trends (2018-2023) (USD Million)
Table 24.78 Biomarker Solutions Market for Diagnosis, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.79 Digital Biomarker Solutions Market for Early Detection, Historical Trends (2018-2023) (USD Million)
Table 24.80 Digital Biomarker Solutions Market for Early Detection, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.81 Biomarker Solutions Market for Predictive Insights, Historical Trends (2018-2023) (USD Million)
Table 24.82 Digital Biomarker Solutions Market for Predictive Insights, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.83 Digital Biomarker Solutions Market: Distribution by Type of Biomarker, 2018, 2024 and 2035
Table 24.84 Digital Biomarker Solutions Market for Physiological Biomarkers, Historical Trends (2018-2023) (USD Million)
Table 24.85 Digital Biomarker Solutions Market for Physiological Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.86 Digital Biomarker Solutions Market for Vocal Biomarkers, Historical Trends (2018-2023) (USD Million)
Table 24.87 Digital Biomarker Solutions Market for Vocal Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.88 Digital Biomarker Solutions Market for Cognitive Biomarkers, Historical Trends (2018-2023) (USD Million)
Table 24.89 Digital Biomarker Solutions Market for Cognitive Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.90 Digital Biomarker Solutions Market for Idiosyncratic Biomarkers, Historical Trends (2018-2023) (USD Million)
Table 24.91 Digital Biomarker Solutions Market for Idiosyncratic Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.92 Digital Biomarker Solutions Market for Other Biomarkers, Historical Trends (2018-2023) (USD Million)
Table 24.93 Digital Biomarker Solutions Market for Other Biomarkers, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.94 Digital Biomarker Solutions Market: Distribution by Therapeutic Area, 2018, 2024 and 2035 (USD Million)
Table 24.95 Digital Biomarker Solutions Market for Neurological Disorders, Historical Trends (2018-2023) (USD Million)
Table 24.96 Digital Biomarker Solutions Market for Neurological Disorders, Forecasted Estimates (2024-2035) Conservative, Base and Optimistic Scenario (USD Million)
Table 24.97 Digital Biomarker Solutions Market for Mental Health Disorders, Historical Trends (2018-2023) (USD Million)
Table 24.98 Digital Biomarker Solutions Market for Mental Health Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.99 Digital Biomarker Solutions Market for Cardiovascular Disorders, Historical Trends (2018-2023) (USD Million)
Table 24.100 Digital Biomarker Solutions Market for Cardiovascular Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.101 Digital Biomarker Solutions Market for Infectious Diseases, Historical Trends (2018-2023) (USD Million)
Table 24.102 Digital Biomarker Solutions Market for Infectious Diseases, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.103 Digital Biomarker Solutions Market for Respiratory Disorders, Historical Trends (2018-2023) (USD Million)
Table 24.104 Digital Biomarker Solutions Market for Respiratory Disorders, Historical Trends (2018-2023) (USD Million)
Table 24.105 Digital Biomarker Solutions Market for Autoimmune Disorders, Historical Trends (2018-2023) (USD Million)
Table 24.106 Digital Biomarker Solutions Market for Autoimmune Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.107 Digital Biomarker Solutions Market for Substance Abuse Disorders, Historical Trends (2018-2023) (USD Million)
Table 24.108 Digital Biomarker Solutions Market for Substance Abuse Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.109 Digital Biomarker Solutions Market for Other Disorders, Historical Trends (2018-2023) (USD Million)
Table 24.110 Digital Biomarker Solutions Market for Other Disorders, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.111 Digital Biomarker Solutions Market: Distribution by Business Model, 2018, 2024 and 2035
Table 24.112 Digital Biomarker Solutions Market for B2B Model, Historical Trends (2018-2023) (USD Million)
Table 24.113 Digital Biomarker Solutions Market for B2B Model, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.114 Digital Biomarker Solutions Market for B2C Model, Historical Trends (2018-2023) (USD Million)
Table 24.115 Digital Biomarker Solutions Market for B2C Model, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.116 Digital Biomarker Solutions Market: Distribution by Key Geographical Regions, 2018, 2024 and 2035
Table 24.117 Digital Biomarker Solutions Market in North America, Historical Trends (2018-2023) (USD Million)
Table 24.118 Digital Biomarker Solutions Market in North America, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.119 Digital Biomarker Solutions Market in Europe, Historical Trends (2018-2023) (USD Million)
Table 24.120 Digital Biomarker Solutions Market in Europe, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.121 Digital Biomarker Solutions Market in Asia-Pacific, Historical Trends (2018-2023) (USD Million)
Table 24.122 Digital Biomarker Solutions Market in Asia-Pacific, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.123 Digital Biomarker Solutions Market in Middle East and North Africa, Historical Trends (2018-2023) (USD Million)
Table 24.124 Digital Biomarker Solutions Market in Middle East and North Africa, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)
Table 24.125 Digital Biomarker Solutions Market in Rest of the World, Historical Trends (2018-2023) (USD Million)
Table 24.126 Digital Biomarker Solutions Market in Rest of the World, Forecasted Estimates (2024-2035), Conservative, Base and Optimistic Scenario (USD Million)

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Acculi Labs
  • ActiGraph
  • AliveCor
  • ATCOR
  • BACtrack
  • Biogen
  • BioSerenity
  • BioSensics
  • Eyenuk
  • Empatica
  • Feel Therapeutics
  • icometrix
  • iMediSync
  • IXICO
  • Kinsa
  • Koneksa Health
  • Kontigo Care
  • Progentec Diagnostics
  • Quibim
  • Vocalis Health

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Digital Biomarkers: Global Markets - Product Image

Digital Biomarkers: Global Markets

  • Report
  • 129 Pages
  • Global
From
Psychiatric Digital Biomarkers Market Size, Share & Trends Analysis Report by Type (Wearables, Mobile-Based Applications, Sensors), Clinical Practice (Diagnostic, Monitoring, Predictive & Prognostic), End-Use, and Region with Growth Forecasts, 2025-2030 - Product Image

Psychiatric Digital Biomarkers Market Size, Share & Trends Analysis Report by Type (Wearables, Mobile-Based Applications, Sensors), Clinical Practice (Diagnostic, Monitoring, Predictive & Prognostic), End-Use, and Region with Growth Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From
Digital Biomarkers Market by Component (Hardware, Software), Biomarker Type (Active, Passive), Functionality, Therapeutic Area, Application, End User - Global Forecast 2025-2030 - Product Image

Digital Biomarkers Market by Component (Hardware, Software), Biomarker Type (Active, Passive), Functionality, Therapeutic Area, Application, End User - Global Forecast 2025-2030

  • Report
  • 189 Pages
  • Global
From
Psychiatric Digital Biomarkers - Global Strategic Business Report - Product Image

Psychiatric Digital Biomarkers - Global Strategic Business Report

  • Report
  • 386 Pages
  • Global
From
Digital Biomarkers - Market Insights, Competitive Landscape, and Market Forecast - 2032 - Product Image

Digital Biomarkers - Market Insights, Competitive Landscape, and Market Forecast - 2032

  • Report
  • 150 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.